DEF 14A: Moderna Seeks Shareholder Approval for Key Governance Changes, Executive Pay

Moderna's proxy statement outlines proposals for the upcoming annual meeting, including director elections, executive compensation, and amendments to the company's certificate of incorporation.

Summary

• Moderna is holding its Annual Meeting of Shareholders on May 6, 2024, to vote on several key proposals.
• The proposals include electing three Class III directors, approving executive compensation on an advisory basis, ratifying the appointment of Ernst & Young LLP as the independent auditor, and amending the Certificate of Incorporation to allow shareholders to call a special meeting and to reflect new Delaware law provisions allowing for officer exculpation.
• The Board of Directors recommends voting FOR all nominees and proposals.
• In 2023, Moderna achieved $6.7 billion in net product sales from COVID-19 vaccines and held a 48% U.S. market share for COVID-19 vaccine sales to the retail market.
• The company has $13.3 billion in cash, cash equivalents, and investments as of December 31, 2023, and 45 programs in development.
• Moderna expects to launch up to 15 products in the next five years, with up to four of those launches possibly occurring by 2025.

Sentiment

Score: 6

Explanation: The document presents a mixed sentiment. While there are positive aspects such as pipeline advancement and market share growth, the financial underperformance and executive compensation adjustments temper the overall outlook.

Positives

• Moderna achieved 48% U.S. retail market share for its COVID-19 vaccine in 2023, up from 37% in 2022.
• The company has nine late-stage programs in development, including seven in Phase 3.
• The 2021-2023 PSU program resulted in a maximum payout, with a vesting percentage of 200% of target.
• The Board approved updates to the company's bylaws to adopt majority voting for uncontested director elections and to implement a proxy access bylaw.
• The company is anticipating approval and preparing for commercial launch of its RSV vaccine in 2024.

Negatives

• Corporate performance did not meet expectations for financial goals, falling short on product sales and operating income objectives.
• Executive Committee members, including the CEO, received bonuses at 81% of target due to corporate performance not meeting expectations.
• All stock options granted from 2021 through 2023 were underwater as of December 31, 2023, with exercise prices significantly above prevailing stock prices.

Risks

• Expected product launches are subject to clinical trial, regulatory, and commercial success, as well as the availability of supply.
• The market for COVID-19 vaccines is evolving, with sales shifting significantly to the second half of the year and lower demand than in 2021 and 2022.
• The company's operating loss of $4.2 billion for 2023 fell significantly short of internal targets.

Future Outlook

Moderna expects to launch up to 15 products in the next five years, with up to four of those launches possibly occurring by 2025. The company is focused on commercial execution, disciplined investment, and advancing its late-stage pipeline to drive organic sales growth.

Management Comments

• Modernas mission is to deliver the greatest possible impact to people through mRNA medicines.
• The company is focused on commercial execution to drive sales growth and profitability.
• Moderna plans to continue to review its cost structure to find efficiencies and remain disciplined around spending.
• The company is focused on advancing its late-stage pipeline to drive organic sales growth.

Industry Context

Moderna is a leader in the creation of the field of mRNA medicines. The company's mRNA platform has enabled the development of therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases, and autoimmune diseases. Moderna competes with other pharmaceutical and biotechnology companies for talent, market share, and research and development opportunities.

Comparison to Industry Standards

• The document references IQVIA data for market share, indicating a comparison to industry-wide sales data.
• The document compares Moderna's CEO total realizable pay to stock price performance against a peer group of companies of comparable size and business.
• The peer group includes AbbVie, BioMarin Pharmaceutical, Merck, Alnylam Pharmaceuticals, Bristol-Myers Squibb, Pfizer, Amgen, Eli Lilly, Regeneron Pharmaceuticals, BeiGene Ltd., Gilead Sciences, Seagen (fka Seattle Genetics), Biogen, Incyte Corporation, and Vertex Pharmaceuticals.
• The document mentions the Nasdaq Biotechnology Index as a benchmark for TSR performance.

Management Changes

Corporate Governance

Stakeholder Impact

• Shareholders: The proposals aim to enhance shareholder rights and align executive compensation with company performance.
• Employees: The document discusses talent management, diversity and inclusion initiatives, and employee engagement.
• Customers: The company is focused on delivering innovative therapies and vaccines to address unmet medical needs.
• The company is committed to protecting the planet and minimizing its impact on the environment.

Next Steps

• Shareholders are encouraged to vote on the proposals outlined in the proxy statement.
• The company will file a Certificate of Amendment to the Certificate of Incorporation if the Special Meeting Amendment is approved at the Annual Meeting.
• The company will file a Certificate of Amendment to the Certificate of Incorporation if the Exculpation Amendment is approved at the Annual Meeting.

Key Dates

Keywords

Moderna, proxy statement, shareholders, directors, executive compensation, corporate governance, COVID-19, vaccine, RSV, amendment, certificate of incorporation, officer exculpation, special meeting, Ernst & Young, audit